Stock Price Movement and Market Context
On 1 Dec 2025, Ambalal Sarabhai Enterprises recorded its lowest price in the past year at Rs.28.1. Despite this, the stock outperformed its sector by 1.03% during the trading session and showed a modest gain following three consecutive days of decline. However, the share price remains below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating sustained downward pressure over multiple timeframes.
In contrast, the broader market has exhibited resilience. The Sensex opened at 86,065.92 points, gaining 359.25 points (0.42%) before trading slightly lower at 85,861.27 points (0.18%). The index is currently within 0.23% of its 52-week high of 86,055.86 points and has recorded a three-week consecutive rise, accumulating a 1.54% gain over this period. Small-cap stocks have led the market rally, with the BSE Small Cap index advancing by 0.4% today.
Long-Term and Recent Performance Analysis
Ambalal Sarabhai Enterprises’ stock has experienced a substantial decline over the past year, with a total return of -49.97%. This contrasts sharply with the Sensex’s 7.61% return over the same period. The stock’s 52-week high was Rs.68, highlighting the extent of the price contraction.
Over the last five years, the company’s net sales have grown at an annual rate of 7.00%, reflecting modest expansion within the Pharmaceuticals & Biotechnology sector. However, the company’s long-term return on capital employed (ROCE) has averaged 4.55%, which is relatively low for the industry and suggests limited efficiency in generating returns from its capital base.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Quarterly and Cash Flow Indicators
The company’s recent quarterly results indicate challenges in profitability. Profit before tax (PBT) for the latest quarter was reported at a loss of Rs.1.66 crore, representing a decline of 548.6% compared to the average of the previous four quarters. Similarly, the profit after tax (PAT) stood at a loss of Rs.0.56 crore, down by 111.3% relative to the prior four-quarter average.
Operating cash flow for the year was recorded at a negative Rs.17.62 crore, marking the lowest level in recent periods. These figures point to constrained cash generation and profitability pressures in the near term.
Comparative Performance and Valuation Metrics
Ambalal Sarabhai Enterprises has underperformed the BSE500 index across multiple time horizons, including the last three years, one year, and three months. Despite this, the company’s return on capital employed for the most recent period is 1.5%, and it maintains an enterprise value to capital employed ratio of 1.4. These valuation metrics suggest the stock is trading at a discount relative to its peers’ historical averages.
Over the past year, while the stock price has declined by nearly half, the company’s profits have shown a rise of 24.8%. The price-to-earnings-to-growth (PEG) ratio stands at 0.5, indicating a valuation that may reflect the current earnings growth relative to the stock price.
Shareholding and Market Position
The majority of Ambalal Sarabhai Enterprises’ shares are held by non-institutional investors. The company operates within the Pharmaceuticals & Biotechnology sector, which has seen varied performance across its constituents. While the broader market and small-cap segments have shown positive momentum, Ambalal Sarabhai’s stock remains subdued.
Considering Ambalal Sarabhai Enterprises ? Wait! SwitchER has found potentially better options in Pharmaceuticals & Biotechnology and beyond. Compare this micro-cap with top-rated alternatives now!
- - Better options discovered
- - Pharmaceuticals & Biotechnology + beyond scope
- - Top-rated alternatives ready
Summary of Current Position
Ambalal Sarabhai Enterprises’ stock has reached a significant low point in its 52-week trading range, reflecting a combination of subdued financial performance and market dynamics. While the broader market indices and small-cap segments have shown strength, this particular stock continues to trade below key technical levels and has experienced notable declines in profitability and cash flow.
The company’s valuation metrics indicate a discount relative to peers, and recent profit growth contrasts with the stock’s price movement. These factors contribute to the current market assessment of the stock within the Pharmaceuticals & Biotechnology sector.
Get 1 year of Weekly Picks FREE when you subscribe to MojoOne. Offer ends soon. Start Saving Now →
